Patients with previously treated metastatic pancreatic cancer lived an average of 13 additional months with Revolution Medicines' new drug, daraxonrasib, more than double the survival rate of standard chemotherapy. The drug's results are a critical advancement in a disease area historically resistant to effective therapies, according to The Washington Post.
However, daraxonrasib dramatically extends survival, yet nearly a third of patients experience severe side effects, including widespread rash and debilitating gastrointestinal issues. The severe side effects experienced by nearly a third of patients, including widespread rash and debilitating gastrointestinal issues, present a difficult choice for patients facing a dire prognosis.
Daraxonrasib is poised to become a new standard of care for metastatic pancreatic cancer, demanding careful patient selection and management of its significant adverse reactions.
